Every Form 4 that Axogen, Inc. (AXGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AXGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AXGN filings page.
Axogen, Inc. (AXGN) director Joseph A. Tyndall reported selling 3,500 shares of common stock on September 2, 2026 in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. The weighted average sale price was about $49.70 per share, and he now directly holds 10,650 shares of Axogen common stock.
Axogen, Inc. executive Marc A. Began, EVP & General Counsel, exercised 67,500 Employee Stock Options at an exercise price of $8.16 per share on August 10, 2026, receiving an equal number of common shares. On the same date, he sold 67,500 common shares at a weighted average price of $47.345 per share in transactions executed pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2026. Following the option exercise, 22,500 options from this grant remained outstanding, expiring on March 1, 2033, under a vesting schedule that completes on March 1, 2027.
Axogen, Inc. director Amy McBride exercised an employee stock option for 13,353 shares of common stock at an exercise price of $14.85 per share and on the same date sold 13,353 shares of common stock at a weighted average price of $48.423 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on May 12, 2026. All shares underlying the option had been fully vested since May 14, 2018.
Axogen, Inc. director Kathy Johnson Weiler reported selling 14,150 shares of common stock on August 7, 2026 in a sale classified as an open market or private transaction. The weighted average sale price was $45.298 per share, with individual trades ranging from $44.43 to $46.47. Following this transaction, the reporting person held 0 shares directly. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
Burke William P. Mr. reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director William P. Burke received a grant of 4,392 restricted stock units as equity compensation for his service on the Board of Directors. Each restricted stock unit represents a contingent right to receive one share of Axogen common stock. The annual equity grant is based on a $185,000 valuation as of the grant date and will vest on June 24, 2027. Following this grant, Burke holds 4,392 restricted stock units directly.
JOHNSON JOHN reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director John Johnson received an annual equity grant of 4,392 restricted stock units (RSUs) as compensation for serving on the Board of Directors. Each RSU represents a contingent right to receive one share of Axogen common stock. The award is based on a $185,000 valuation as of the grant date and is scheduled to vest on June 24, 2027, the one-year anniversary of the grant date, subject to the stated service conditions.
Levine Alan M reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Alan M. Levine received an annual equity award in the form of 4,392 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Axogen common stock. The grant is valued at $185,000 as of the grant date.
The RSUs were awarded for service on the Board of Directors and vest on June 24, 2027, the one-year anniversary of the grant date. Following this grant, Levine directly holds 4,392 RSUs linked to Axogen common stock.
THOMAS PAUL reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Paul Thomas reported receiving a grant of 5,579 restricted stock units as equity compensation for his Board service. Each unit represents one share of common stock and the award is valued at $235,000 as of the grant date. The restricted stock units vest on June 24, 2027, the one-year anniversary of the grant date, and Thomas’s directly held derivative position from this grant totals 5,579 units after the transaction.
Axogen, Inc. director Joseph A. Tyndall received a grant of 4,392 restricted stock units as equity compensation for his service on the Board of Directors. Each unit represents a contingent right to receive one share of Axogen common stock.
The annual equity grant is based on a $185,000 valuation as of the grant date and will vest on June 24, 2027, the one-year anniversary of the grant. Following this award, Tyndall holds 4,392 restricted stock units directly, reflecting a routine compensation-related acquisition rather than an open-market purchase.
Weiler Kathy Johnson reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Kathy Johnson Weiler received a grant of 4,392 restricted stock units as annual equity compensation for her service on the board. Each unit represents a contingent right to receive one share of Axogen common stock. The grant is valued at $185,000 as of the grant date and will vest on June 24, 2027, the one-year anniversary of the grant date. Following this award, she holds 4,392 restricted stock units directly.
Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Wendell Amy McBride received an annual equity grant of restricted stock units for service on the Board of Directors. The award covers 4,392 restricted stock units, each representing a right to receive one share of common stock, based on a $185,000 valuation as of the grant date. These units vest on June 24, 2027, the one-year anniversary of the grant date, and reflect compensation rather than an open‑market share purchase.
Axogen, Inc. director Alan M. Levine reported the vesting of restricted stock units and corresponding acquisition of common shares as part of his annual board compensation. On June 19, 2026, 14,150 restricted stock units vested, converting into 14,150 shares of Axogen common stock at no cash exercise price.
Each unit represented the right to receive one share, based on an equity grant valued at $150,000 as of the grant date. After this vesting and conversion, Levine directly holds 50,893 shares of Axogen common stock, reflecting a compensation-related, non‑market transaction rather than an open‑market purchase or sale.
Axogen, Inc. director Kathy Johnson Weiler acquired 14,150 shares of common stock through the vesting of restricted stock units on June 19, 2026. These 14,150 restricted stock units converted into an equal number of common shares at a price of $0.00 per share as part of her annual equity compensation for Board service, which was originally valued at $150,000 on the grant date. Following the vesting and conversion, she directly holds 14,150 shares of Axogen common stock, and the reported restricted stock units from this grant are fully settled.
Axogen, Inc. director Wendell Amy McBride acquired 14,150 shares of common stock through the vesting and conversion of restricted stock units on June 19, 2026. These RSUs were an annual equity grant for Board service, valued at $150,000 as of the grant date.
Each vested unit converted into one share of Axogen common stock, increasing McBride’s directly held position to 107,976 shares after the transaction. This is a compensation-related derivative exercise, not an open-market purchase or sale.
Axogen, Inc. director THOMAS PAUL acquired 18,867 shares of common stock through the vesting of restricted stock units on June 19, 2026. These 18,867 restricted stock units converted into an equal number of common shares as they vested, reflecting an annual equity grant for service on the Board.
The equity grant was based on a $200,000 valuation as of the original grant date and vested on the one-year anniversary of that date. Following this vesting and conversion, Paul directly holds 32,395 shares of Axogen common stock.
TYNDALL JOSEPH A. reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Joseph A. Tyndall reported the vesting of 14,150 restricted stock units on June 19, 2026, which were settled into 14,150 shares of common stock. Each restricted stock unit represented a right to receive one share upon vesting, reflecting an annual equity grant for board service valued at $150,000 on the grant date. This filing shows a compensation-related equity award vesting, not an open-market stock purchase or sale.
Axogen, Inc. director John Johnson acquired 14,150 shares of common stock through the vesting and conversion of 14,150 restricted stock units on June 19, 2026. Each restricted stock unit represented a right to receive one Axogen common share. These RSUs were an annual equity grant for board service, based on a $150,000 valuation at the grant date and scheduled to vest on the one-year anniversary of that grant.
Axogen, Inc. director William P. Burke reported a routine equity compensation event. On June 19, 2026, 14,150 restricted stock units vested and were delivered as 14,150 shares of common stock, reflecting an annual equity grant for his service on the Board of Directors.
Each restricted stock unit represented a right to receive one share of Axogen common stock. Following this vesting and conversion, Burke directly holds 14,250 shares of common stock. No open-market purchases or sales were reported, and there are no remaining derivative holdings from this RSU grant.
Axogen, Inc. director Wendell Amy McBride exercised stock options and sold the resulting shares. On May 8, 2026, she exercised options covering 1,647 shares of common stock at $14.85 per share, then completed an open-market sale of 1,647 shares at a weighted average price of $42.60 per share, with individual sale prices ranging from $42.50 to $42.62. After these transactions, she directly held 93,826 shares of Axogen common stock.
Axogen, Inc. director John Johnson exercised stock options and sold the resulting shares. On May 7, 2026, he exercised options covering 11,050 shares of common stock at $7.04 per share, then sold 11,050 shares in open-market transactions at a weighted average price of $43.255 per share. The sale price reflected multiple trades between $43.25 and $43.35 per share. Following these transactions, Johnson reported holding 0 shares of Axogen common stock directly, and the exercised option grant was fully used.
Axogen, Inc. director Kathy Johnson Weiler exercised options to acquire 16,344 shares of common stock at $6.95 per share, then sold the same 16,344 shares in an open‑market transaction at a weighted average price of $44.091 per share on May 7, 2026.
Following these transactions, she reports holding no common shares directly but retains 27,307 employee stock options with a $6.95 exercise price expiring on December 20, 2033. According to the grant terms, these options vest in three equal annual installments beginning on December 20, 2024.
Axogen, Inc. Chief Marketing Officer Jens Kemp reported an open-market sale of 4,000 shares of Axogen common stock. The weighted average sale price was $43.4403 per share, with individual trades executed between $43.44 and $43.45 per share. Following these transactions, Kemp directly owns 72,451 shares of Axogen common stock.
Axogen, Inc. CFO Lindsey Marie Hartley reported an option-related share transaction. On May 7, 2026, she exercised employee stock options to acquire a total of 5,463 shares of common stock at exercise prices of $8.20 and $8.27 per share, and sold 1,051 shares in open-market transactions at $43.67 per share. The options exercised were or will be fully vested under schedules that reach full vesting in March 2026 and March 2027, reflecting routine compensation-related activity.
Axogen, Inc. Sales VP Doris Quackenbush reported an open‑market sale of 3,878 shares of common stock on May 7, 2026. The shares were sold at a weighted average price of $43.507 per share in multiple trades between $43.50 and $44.00. After this transaction, Quackenbush directly holds 92,416 shares of Axogen common stock, as reported in the filing.
Axogen, Inc. Chief Innovation Officer Erick Wayne DeVinney exercised restricted stock units and made related share transactions. On March 16, 2026, 17,938 restricted stock units vested and were converted into an equal number of common shares. Of these, 2,870 shares were withheld by Axogen at $32.84 per share to cover tax obligations, which the company states is not an open-market sale. DeVinney also sold 5,221 common shares in an open-market transaction at $32.84 per share. Following these transactions, he directly holds 262,781 shares of Axogen common stock.
Axogen, Inc. CFO Lindsey Marie Hartley reported routine equity compensation activity tied to restricted stock units (RSUs) vesting on March 16, 2026. She exercised RSUs covering 9,000 shares of common stock, consistent with the plan that each RSU delivers one share when it vests.
To satisfy tax withholding obligations, the issuer withheld 3,542 shares of common stock at $32.84 per share rather than executing any open-market sale. After these RSU conversions and tax withholdings, Hartley holds 60,734 shares of Axogen common stock directly.
Axogen, Inc.’s Chief Marketing Officer, Jens Kemp, reported equity compensation changes and related tax-withholding transactions. On February 26, 2026, he was granted 23,000 restricted stock units (RSUs) and 50,670 shares of common stock as awards at no purchase price.
The RSUs vest fully on February 26, 2030, with 50% vesting on February 26, 2028 and 25% vesting on each of the next two yearly anniversaries. To cover withholding tax from vesting PSUs and RSUs, the issuer withheld 15,414 shares at $31.90 and 2,952 shares at $30.65, and no shares were sold by Kemp. Following these transactions, he directly holds 76,451 shares of common stock and 23,000 RSUs, and a prior overstatement of his beneficial ownership by 4,003 shares has been corrected.
Axogen, Inc. Chief Innovation Officer Erick Wayne DeVinney reported equity compensation and related tax-withholding transactions. On February 26, 2026, he received grants of 23,000 restricted stock units and 33,780 shares of common stock as awards, at no cash cost per share.
The filing also shows dispositions of 11,276 shares and 10,702 shares of common stock identified as tax-withholding transactions, used to cover tax liabilities from the vesting of performance stock units and restricted stock units. Footnotes clarify that no shares were sold by the reporting person in these dispositions.
Each restricted stock unit represents one share of Axogen common stock. The RSU award is scheduled to fully vest on February 26, 2030, with 50% vesting on February 26, 2028 and an additional 25% vesting each 12 months thereafter, with shares delivered upon each vesting date.
Axogen, Inc. executive vice president and general counsel Marc A. Began reported several equity compensation transactions. On February 26, 2026, he received a grant of 23,000 restricted stock units (RSUs), which vest through February 26, 2030 under a multi-year schedule.
On February 26, 2026 and March 1, 2026, performance stock units and RSUs vested, leading to the acquisition and delivery of 11,250 shares of common stock at no cost via derivative exercises. In connection with these vestings, 8,753 shares at $31.90 and 4,427 shares at $30.65 of common stock were withheld to cover tax liabilities; the footnotes state that no shares were sold by Began.
Axogen, Inc. reported equity compensation changes for CFO Lindsey Marie Hartley. On February 26, 2026, she acquired 23,000 restricted stock units (RSUs), each representing a contingent right to receive one share of Axogen common stock.
On the same date, 17,453 shares of common stock became vested upon attainment and certification of performance criteria, increasing her direct common stock holdings. 6,630 shares of common stock at $31.90 per share were withheld to satisfy tax obligations related to these awards and did not involve an open market sale. After these transactions, she directly owned 55,276 shares of common stock and 23,000 RSUs, with the RSUs scheduled to vest 50% on February 26, 2028 and the remainder annually until fully vested on February 26, 2030.
DALE MICHAEL D reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. reported that Chief Executive Officer Michael D Dale received a grant of 98,000 restricted stock units (RSUs) on February 26, 2026. Each RSU represents a contingent right to receive one share of Axogen common stock. The RSUs vest over four years: 50% of the shares vest on February 26, 2028, with an additional 25% vesting on February 26, 2029 and the final 25% on February 26, 2030. Vested shares will be delivered to the CEO on each vesting date, aligning his compensation more closely with the company’s long-term stock performance.
Axogen, Inc. CFO Lindsey Marie Hartley reported equity compensation activity involving restricted stock units and common shares. She received a grant of 17,500 restricted stock units, each representing a contingent right to one share of Axogen common stock. On the same date, she also acquired 17,500 shares of common stock, increasing her direct common stock holdings to 51,157 shares before tax withholding.
To cover tax obligations from vesting restricted stock units, 6,704 common shares were withheld by Axogen at $35.38 per share, reducing her directly held common stock to 44,453 shares. According to the vesting schedule, all shares underlying the restricted stock units will be fully vested on February 22, 2028, with 50% vesting on February 22, 2026 and an additional 25% vesting each of the next two years.
Axogen, Inc. director reports stock option exercises and share sales. On 12/16/2025, the reporting person exercised three non-qualified stock option grants for 5,000, 20,436 and 18,248 shares of Axogen common stock at exercise prices of $8.95, $6.30 and $7.04 per share. On the same date, they sold 5,000, 20,436 and 18,248 shares at a weighted average sale price of $29.312 per share, with individual sale prices ranging from $28.99 to $29.63. After these transactions, the reporting person directly beneficially owned 93,826 shares of Axogen common stock, and the reported option grants had zero derivative securities remaining.
Axogen, Inc. director stock transactions: On 12/16/2025, a director of Axogen, Inc. exercised employee stock options to acquire 18,248 shares of common stock at $7.04 per share and 21,825 shares at $6.95 per share. These exercises increased the director’s direct holdings to 46,653 shares.
On the same date, the director sold 18,248 shares and 21,825 shares at a weighted average sale price of $29.547 per share, and an additional 6,580 shares at $29.55 per share. After these transactions, the director held 0 shares of common stock directly and 43,651 employee stock options, which are exercisable for Axogen common stock.
Axogen, Inc. reported an equity transaction by its Chief Financial Officer. On 12/15/2025, the CFO exercised an employee stock option to acquire 14,812 shares of Axogen common stock at an exercise price of $8.27 per share. On the same date, the CFO sold 14,812 shares of common stock at a weighted average sale price of $29.8605 per share, leaving 31,376 shares of common stock beneficially owned directly after the transactions.
The derivative position tied to this option was reduced to zero following the exercise. The option related to 14,812 underlying shares of Axogen common stock and was scheduled to be fully vested by March 16, 2027 under a vesting schedule where 50% vested on March 16, 2025 and an additional 12.5% vested every six months thereafter.
Axogen, Inc. Chief Executive Officer Michael Dale reported selling 25,000 shares of the company’s common stock on 12/10/2025 at $30 per share. After this sale, he directly beneficially owns 63,537 shares of Axogen common stock.
Axogen, Inc. executive vice president and general counsel Marc Began reported a sale of company stock. On 12/11/2025, he sold 13,222 shares of Axogen common stock at $30 per share. After this transaction, he directly beneficially owns 18,285 shares of Axogen common stock.
Axogen executive Marc Began, EVP & General Counsel, acquired 22,500 shares of Axogen common stock on 12/04/2025 at a reported price of $0 per share. According to the explanation, these shares were issued upon the attainment of certain performance criteria, indicating a performance-based equity award rather than an open-market purchase. Following this transaction, Began beneficially owns 40,785 shares of Axogen common stock.
Axogen (AXGN) insider activity: Director William Burke reported option exercises and open‑market sales executed under a Rule 10b5‑1(c) plan adopted March 14, 2025. On 11/10/2025, he exercised stock options at $8.14 to acquire 19,227 shares, then sold 19,227 shares at a weighted average price of $24.01, with trades ranging from $24.00 to $24.10. On 11/11/2025, he exercised options at $8.14 for 3,591 shares and sold 3,591 shares at a weighted average price of $24.018, with trades from $24.00 to $24.13.
Following these transactions, he directly owned 100 shares. The exercised options carried a $8.14 exercise price and an expiration of July 11, 2032, from a grant that vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022.
Axogen (AXGN) Form 4: Director William Burke reported option exercises and matched open‑market sales executed under a Rule 10b5‑1(c) trading plan adopted March 14, 2025. On 11/05/2025, he exercised 11,431 stock options at $8.14 and sold 11,431 shares at a weighted average price of $24.048, with trades ranging from $24.00 to $24.25. On 11/06/2025, he exercised 5,347 options at $8.14 and sold 5,347 shares at a weighted average of $24.008, with trades from $24.00 to $24.06.
Following these transactions, he held 100 shares of common stock directly. The underlying options are from a grant that vested in three equal annual installments on the anniversary of the July 11, 2022 grant date and carry an expiration of 07/11/2032. The filing shows 22,818 derivative securities beneficially owned after the 11/06 activity.
Axogen, Inc. (AXGN): Director Form 4 activity
Director reported option exercises and same‑day open‑market sales under a Rule 10b5‑1(c) trading plan adopted March 14, 2025. On 10/29/2025, options for 20,436 shares were exercised at $6.30 and sold at a weighted average $19.1542 (shares sold at prices from $19.00 to $19.50). Also on 10/29/2025, options for 19,799 shares were exercised at $8.14 and sold at $22. On 10/30/2025, options for 18,248 shares were exercised at $7.04 and sold at $23.
Following these transactions, direct beneficial ownership of common stock was 100 shares. The $6.30 and $7.04 option grants show 0 remaining after exercise, while the $8.14 grant shows 39,596 derivative securities beneficially owned following the reported transactions.
Axogen, Inc. (AXGN): Form 4 insider transaction — A company director reported a sale of common stock on 10/22/2025. The filing shows 1,457 shares were sold at a weighted average price of $18.018 per share, with individual trades executed between $18.00 and $18.045.
The transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted on March 14, 2025. Following the sale, the reporting person beneficially owns 100 shares directly.